Oncotarget

Research Papers:

Vasohibin-1 suppresses colon cancer

Shuai Liu, Bing Han, Qunyuan Zhang, Jie Dou, Fang Wang, Wenli Lin, Yuping Sun and Guangyong Peng _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:7880-7898. https://doi.org/10.18632/oncotarget.3493

Metrics: PDF 1216 views  |   HTML 1233 views  |   ?  


Abstract

Shuai Liu1,2, Bing Han2,3, Qunyuan Zhang4, Jie Dou2, Fang Wang2, Wenli Lin1, Yuping Sun1 and Guangyong Peng2

1 Department of Oncology, Jinan Central Hospital, Affiliated to Shandong University, Jinan, P. R. China

2 Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO, USA

3 Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, P.R. China

4 Department of Genetics, Washington University School of Medicine, Saint Louis, MO, USA

Correspondence to:

Yuping Sun, email:

Guangyong Peng, email:

Keywords: VASH1, Colon cancer, Angiogenesis, Tumor suppressor, Metastasis

Received: December 10, 2014 Accepted: February 04, 2015 Published: March 08, 2015

Abstract

Vasohibin-1 (VASH1) is an endogenous angiogenesis inhibitor.However, the clinical relevance of VASH1 in colon cancer and its regulations on cancer angiogenesis and cancer cell biological characteristics are still unknown. Here we showed that stromal VASH1 levels were negatively correlated with tumor size, advanced clinical stage and distant metastases in colon cancer patients. Overexpression of VASH1 in colon cancer cells induced apoptosis and senescence, inhibiting cancer cell growth and colony formation in vitro and tumor growth in vivo. In addition, knockdown of VASH1 in cancer cells promoted cell growth, adhesion and migration in vitro, and enhanced tumorigenesis and metastasis in vivo.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3493